Skip to main content
. Author manuscript; available in PMC: 2010 Mar 17.
Published in final edited form as: Nature. 2009 Aug 19;461(7262):402–406. doi: 10.1038/nature08320

Figure 4. Validating kinetin as a candidate compound for treating FD-iPSC derived neural crest cells.

Figure 4

a, Gel image of RT-PCR products for IKBKAP splicing rescued by kinetin treatment in control and FD-iPSC derived neural crest. b, Quantification of band intensity of FD-iPSC derived neural crest cells normalized by GAPDH and the ratio of normal and mutant spliced IKBKAP transcripts. n = 5; *, p < 0.05; ***, P < 0.001. c-d, MASH1 (c) and Tuj1 (d) expression in neuronal differentiation with kinetin treated neural crest cells derived from FD-iPSC . n = 4; ***, P < 0.001. (E-F) Results of wound healing assay (e) and paxillin staining (f) of kinetin treated FD-iPSC derived neural crest cells. n = 4 - 6; ***, P < 0.001. All values are mean ± s. d.